The antiarrhythmic effect of LCZ696 therapy is one of the clinical benefits of the combination of neprilysin inhibitor and ARB, compared to ACEI, since unlike BB [19,20] and MRA [21,22], ACEI does not seem to significantly reduce sudden cardiac death in HF patients [6,7,8]. This evidence concerns the gene MME and hydrops fetalis.